A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

Drug and toxin-induced PAH, Heritable PAH, HIV infection, or congenital heart disease, PAH associated with connective tissue disease, Pulmonary arterial hypertension (PAH) in one of the following groups: Idiopathic PAH

Phase 2 Cohort: Change from Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks, Phase 3 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks

Phase 2 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks, Phase 2 Cohort: Change from Baseline in Mean Right Arterial Pressure (mRAP) at 12 Weeks, Phase 2 Cohort: Change from Baseline in Cardiac Index (CI) at 12 weeks, Phase 2 Cohort: Change from Baseline in Stroke Volume Index (SVI) at 12 weeks, Phase 3 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks, Phase 3 Cohort: Change from Baseline in World Health Organization Functional Class (WHO-FC) at 12 Weeks, Phase 2 and 3 Cohorts: Number of Participants Who Experience an Adverse Event, Phase 2 and 3 Cohorts: Number of Participants Who Discontinue Study Drug Due to an Adverse Event

No related papers found yet.

Belgium, France, Germany, Greece, Italy, Poland, Sweden